Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Biotech

Once a ‘refugee,’ a gene therapy pioneer finds a renewed calling as the field advances

By Damian Garde

The Readout LOUD

LISTEN: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

In rap video, opioid salesmen boasted of their prowess

By Jonathan Saltzman — Boston Globe

Biotech

Something Ventured: Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

Biotech

For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By Rebecca Robbins

Adam's Take

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

By Adam Feuerstein

Biotech

Longevity scientists launch academy to raise profile of life-extending research

By Robert Weisman — Boston Globe

Biotech

MilliporeSigma CEO Udit Batra on gene editing, business in China, and the company’s funky logo

By Kate Sheridan

Biotech

A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial

By Adam Feuerstein

Biotech

Regeneron and Sanofi cut Praluent price 60 percent, as low-selling cholesterol drugs become a drug pricing laboratory

By Matthew Herper

Heavyweights

Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials

By Rick Berke

Business

Real estate tycoon’s investment trust sues his son — and he responds in kind

By Jonathan Saltzman — Boston Globe

Biotech

University of California to be granted long-sought CRISPR patent, possibly reviving dispute with the Broad Institute

By Sharon Begley

Biotech

A tweet from Alexandria Ocasio-Cortez prompts a deeper debate over how drugs are made

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

By Adam Feuerstein

The Readout LOUD

Listen: A bad day for bold biotech, campaign 2020, and where do drugs come from?

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

First attempt at genome editing in U.S. patients produces disappointing — and sobering — results

By Adam Feuerstein

Biotech

Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint

By Matthew Herper

Biotech

New York biotech debuts, targeting dormant metastatic cancer cells

By Sharon Begley

Biotech

Macrogenics offers major surprise with positive breast cancer data, as shares double

By Matthew Herper

Biotech

With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

By Adam Feuerstein

Biotech

After a stormy winter, biotech’s IPO hopes hang on a billion-dollar Alzheimer’s company

By Damian Garde

Biotech

Amicus presents positive data on Pompe drug, but could wait years for approval

By Matthew Herper

Adam's Take

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

By Adam Feuerstein

Biotech

Watch: What is a biosimilar, exactly?

By Damian Garde

Business

Storm clouds gather over pharma companies as price hikes ease

By Matthew Herper

In the Lab

For CRISPR enzymes, the gold rush is on

By Sharon Begley

The Readout LOUD

Listen: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

By Damian Garde and Rebecca Robbins

Health

So good it hurts: Why drug makers looking to replace opioids want to keep some pain in the picture

By Damian Garde

Biotech

Sign up for our Daily Recap newsletter